Spots Global Cancer Trial Database for stage iiic cutaneous melanoma ajcc v7

Every month we try and update this database with for stage iiic cutaneous melanoma ajcc v7 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery	NCT01708941	Recurrent Melan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane...	Ipilimumab Laboratory Biom... Recombinant Int...	18 Years -	National Cancer Institute (NCI)
Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	NCT02097225	BRAF V600E Muta... BRAF V600K Muta... Metastatic Mali... Metastatic Mela... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Unresectable So...	Dabrafenib Laboratory Biom... Onalespib Pharmacological... Trametinib	18 Years -	National Cancer Institute (NCI)
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer	NCT01902173	Hematopoietic a... Locally Advance... Locally Advance... Metastatic Mali... Metastatic Mela... Stage IIIC Cuta... Stage IV Cutane... Unresectable Ma... Unresectable Me...	Biopsy Biospecimen Col... Computed Tomogr... Dabrafenib Mesy... Magnetic Resona... Trametinib Dime... Uprosertib	18 Years -	National Cancer Institute (NCI)
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma	NCT02910700	Metastatic Mali... Metastatic Mela... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Unresectable Me...	Binimetinib Dabrafenib Encorafenib Laboratory Biom... Nivolumab Pharmacological... Trametinib	18 Years -	M.D. Anderson Cancer Center
Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery	NCT03384836	Stage IIIC Cuta... Stage IV Cutane...	Laboratory Biom... Pembrolizumab Propranolol Hyd...	18 Years -	Roswell Park Cancer Institute
Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by Surgery	NCT03325101	Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane...	Cryosurgery Pembrolizumab Pheresis Therapeutic Aut...	18 Years -	Mayo Clinic
Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery	NCT03384836	Stage IIIC Cuta... Stage IV Cutane...	Laboratory Biom... Pembrolizumab Propranolol Hyd...	18 Years -	Roswell Park Cancer Institute
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma	NCT02965716	Advanced Melano... Recurrent Melan... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Unresectable Me...	Pembrolizumab Talimogene Lahe...	18 Years -	National Cancer Institute (NCI)
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery	NCT01274338	Melanoma of Unk... Recurrent Melan... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane...	Ipilimumab Quality-of-Life... Recombinant Int...	12 Years -	National Cancer Institute (NCI)
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery	NCT01274338	Melanoma of Unk... Recurrent Melan... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane...	Ipilimumab Quality-of-Life... Recombinant Int...	12 Years -	National Cancer Institute (NCI)
Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by Surgery	NCT03325101	Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane...	Cryosurgery Pembrolizumab Pheresis Therapeutic Aut...	18 Years -	Mayo Clinic
Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation	NCT02231775	Stage IIIB Cuta... Stage IIIC Cuta...	Dabrafenib Laboratory Biom... Therapeutic Con... Trametinib	18 Years -	M.D. Anderson Cancer Center
Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer	NCT01727076	Head and Neck S... Recurrent Head ... Recurrent Non-S... Recurrent Renal... Recurrent Skin ... Stage III Renal... Stage IIIA Cuta... Stage IIIA Non-... Stage IIIB Cuta... Stage IIIB Non-... Stage IIIC Cuta... Stage IV Cutane... Stage IV Non-Sm... Stage IV Renal ...	Laboratory Biom... Pharmacological... Recombinant Hum...	19 Years -	National Cancer Institute (NCI)
Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma	NCT03276832	Metastatic Mela... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane...	Imiquimod Biopsy Pembrolizumab Computed Tomogr... Positron Emissi... Magnetic Resona...	18 Years -	Mayo Clinic
Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery	NCT03021460	Metastatic Mela... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Unresectable Me...	Ibrutinib Laboratory Biom... Pembrolizumab	18 Years -	Mayo Clinic
Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma	NCT01807182	Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Metastatic Mela...	Aldesleukin Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Therapeutic Tum...	18 Years -	Fred Hutchinson Cancer Center
Neoadjuvant and Adjuvant Checkpoint Blockade	NCT02519322	Cutaneous Melan... Mucosal Melanom... Ocular Melanoma Stage III Acral... Stage IIIB Cuta... Stage IIIB Uvea... Stage IIIC Cuta... Stage IIIC Uvea... Stage IV Acral ... Stage IV Cutane... Stage IV Uveal ...	Ipilimumab Laboratory Biom... Nivolumab Relatlimab Therapeutic Con...	18 Years -	M.D. Anderson Cancer Center
Neoadjuvant and Adjuvant Checkpoint Blockade	NCT02519322	Cutaneous Melan... Mucosal Melanom... Ocular Melanoma Stage III Acral... Stage IIIB Cuta... Stage IIIB Uvea... Stage IIIC Cuta... Stage IIIC Uvea... Stage IV Acral ... Stage IV Cutane... Stage IV Uveal ...	Ipilimumab Laboratory Biom... Nivolumab Relatlimab Therapeutic Con...	18 Years -	M.D. Anderson Cancer Center
Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery	NCT01940809	BRAF V600E Muta... BRAF V600K Muta... Metastatic Mela... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane...	Dabrafenib Ipilimumab Laboratory Biom... Nivolumab Trametinib	18 Years -	National Cancer Institute (NCI)
Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation	NCT02231775	Stage IIIB Cuta... Stage IIIC Cuta...	Dabrafenib Laboratory Biom... Therapeutic Con... Trametinib	18 Years -	M.D. Anderson Cancer Center
Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	NCT02097225	BRAF V600E Muta... BRAF V600K Muta... Metastatic Mali... Metastatic Mela... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Unresectable So...	Dabrafenib Laboratory Biom... Onalespib Pharmacological... Trametinib	18 Years -	National Cancer Institute (NCI)
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery	NCT01134614	Advanced Melano... Metastatic Mela... Recurrent Melan... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Unresectable Me...	Ipilimumab Sargramostim	18 Years -	National Cancer Institute (NCI)
Neoadjuvant and Adjuvant Checkpoint Blockade	NCT02519322	Cutaneous Melan... Mucosal Melanom... Ocular Melanoma Stage III Acral... Stage IIIB Cuta... Stage IIIB Uvea... Stage IIIC Cuta... Stage IIIC Uvea... Stage IV Acral ... Stage IV Cutane... Stage IV Uveal ...	Ipilimumab Laboratory Biom... Nivolumab Relatlimab Therapeutic Con...	18 Years -	M.D. Anderson Cancer Center
Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by Surgery	NCT03325101	Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane...	Cryosurgery Pembrolizumab Pheresis Therapeutic Aut...	18 Years -	Mayo Clinic
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma	NCT02965716	Advanced Melano... Recurrent Melan... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Unresectable Me...	Pembrolizumab Talimogene Lahe...	18 Years -	National Cancer Institute (NCI)
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery	NCT01134614	Advanced Melano... Metastatic Mela... Recurrent Melan... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Unresectable Me...	Ipilimumab Sargramostim	18 Years -	National Cancer Institute (NCI)
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery	NCT01950390	Stage IIIC Cuta... Stage IV Cutane... Unresectable Me...	Bevacizumab Ipilimumab	18 Years -	National Cancer Institute (NCI)
Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer	NCT01480154	Advanced Malign... Stage III Cutan... Stage III Prost... Stage III Renal... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Stage IV Prosta... Stage IV Renal ...	Akt Inhibitor M... Hydroxychloroqu...	18 Years -	National Cancer Institute (NCI)
Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma	NCT02500576	Metastatic Mela... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane...	Aldesleukin Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Pembrolizumab Quality-of-Life... Therapeutic Tum...	18 Years -	M.D. Anderson Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: